LADETTO, Marco
 Distribuzione geografica
Continente #
NA - Nord America 19.783
EU - Europa 12.125
AS - Asia 8.977
SA - Sud America 1.428
Continente sconosciuto - Info sul continente non disponibili 1.069
AF - Africa 318
OC - Oceania 127
Totale 43.827
Nazione #
US - Stati Uniti d'America 18.872
SG - Singapore 3.172
IT - Italia 3.078
CN - Cina 2.882
DE - Germania 2.118
FR - Francia 1.132
BR - Brasile 975
SE - Svezia 881
IE - Irlanda 864
VN - Vietnam 829
GB - Regno Unito 637
UA - Ucraina 623
FI - Finlandia 604
AT - Austria 569
CA - Canada 516
KR - Corea 391
JP - Giappone 353
ES - Italia 326
HK - Hong Kong 290
IN - India 259
PL - Polonia 257
NL - Olanda 175
RU - Federazione Russa 163
CH - Svizzera 151
AR - Argentina 126
MX - Messico 114
SN - Senegal 112
BD - Bangladesh 109
ID - Indonesia 106
BE - Belgio 105
CL - Cile 102
AU - Australia 98
TR - Turchia 84
IL - Israele 79
GR - Grecia 78
IQ - Iraq 75
DK - Danimarca 74
CO - Colombia 73
JM - Giamaica 54
SA - Arabia Saudita 54
CR - Costa Rica 49
EC - Ecuador 45
VE - Venezuela 41
ZA - Sudafrica 41
MA - Marocco 40
PT - Portogallo 39
RO - Romania 39
UZ - Uzbekistan 39
EU - Europa 38
PE - Perù 38
TW - Taiwan 37
NO - Norvegia 30
PH - Filippine 29
NZ - Nuova Zelanda 28
CZ - Repubblica Ceca 27
PK - Pakistan 27
DZ - Algeria 25
RS - Serbia 24
HU - Ungheria 23
HN - Honduras 22
TH - Thailandia 22
TT - Trinidad e Tobago 22
MY - Malesia 21
EG - Egitto 20
GT - Guatemala 20
IR - Iran 19
LT - Lituania 19
TN - Tunisia 19
NI - Nicaragua 18
PR - Porto Rico 18
SC - Seychelles 18
BY - Bielorussia 15
JO - Giordania 14
BG - Bulgaria 13
LB - Libano 12
PA - Panama 12
UY - Uruguay 12
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
CU - Cuba 10
AL - Albania 9
LU - Lussemburgo 9
SV - El Salvador 9
DO - Repubblica Dominicana 8
HR - Croazia 8
NP - Nepal 8
AP - ???statistics.table.value.countryCode.AP??? 7
GP - Guadalupe 7
KE - Kenya 7
KZ - Kazakistan 7
AO - Angola 6
BB - Barbados 6
OM - Oman 6
AM - Armenia 5
AZ - Azerbaigian 5
BS - Bahamas 5
EE - Estonia 5
ET - Etiopia 5
KW - Kuwait 5
MK - Macedonia 5
Totale 42.698
Città #
Ashburn 1.980
Singapore 1.720
Beijing 1.539
Chandler 1.258
Santa Clara 948
San Jose 873
Dublin 852
Houston 621
Vienna 518
Council Bluffs 510
Milan 509
Fairfield 501
Jacksonville 437
Wilmington 420
Ann Arbor 410
Villeurbanne 341
Dearborn 326
Medford 309
Torino 299
Nyköping 293
Woodbridge 293
Columbus 266
Seattle 261
Princeton 258
Los Angeles 252
Redwood City 247
Rome 244
The Dalles 239
Hong Kong 229
Munich 219
Ho Chi Minh City 214
Lauterbourg 197
Warsaw 189
San Mateo 186
Hanoi 185
Cambridge 169
Dallas 161
Tokyo 161
New York 151
Buffalo 149
Helsinki 142
Toronto 142
Turin 133
Shanghai 127
Boardman 125
Pisa 111
Duncan 109
Fremont 109
Guangzhou 103
Paris 94
Boston 92
Santiago 92
São Paulo 91
London 85
Washington 78
Nutley 77
Turku 75
Dong Ket 73
Nürnberg 70
Florence 68
Atlanta 67
Bologna 67
Seoul 67
Phoenix 65
Jakarta 64
Hangzhou 61
Chicago 60
Brussels 58
Norwalk 58
Nanjing 55
Hefei 54
Philadelphia 54
Düsseldorf 50
Nuremberg 50
Brooklyn 47
Naples 47
Orem 47
Montreal 46
Frankfurt am Main 45
Detroit 41
Madrid 41
Raritan 41
San José 40
Jinan 39
Miano 39
Tianjin 38
Verona 38
Chengdu 37
San Diego 36
Amsterdam 35
North Bergen 35
Da Nang 32
Haiphong 32
Silver Spring 32
Zhengzhou 31
Chennai 30
Palermo 30
Lima 29
Ottawa 29
Redondo Beach 29
Totale 22.726
Nome #
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2.035
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1.242
Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 942
Esmo consensus conferences: Guidelines on malignant lymphoma. Part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma 700
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 635
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 629
Newly diagnosed and relapsed follicular lymphoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up 608
Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 605
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 601
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 507
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 490
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 409
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 404
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 403
Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 372
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 335
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 325
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 304
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 295
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 294
Home management of hematological patients requiring hospital admission 281
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 272
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 265
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 258
Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials 254
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 250
Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome 247
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 246
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 245
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 231
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 228
Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL) 225
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 224
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 223
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 220
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 220
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 214
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 213
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS 212
Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638) 207
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 204
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 202
High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 202
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. 197
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 197
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 196
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 195
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 193
Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma 192
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 192
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 191
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 190
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 188
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 188
Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis 187
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 187
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 185
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 183
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 183
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 182
Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial 182
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 182
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 182
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 181
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 180
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 180
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 180
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 179
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. 179
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 178
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 178
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 178
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 178
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 178
Droplet Digital PCR Assay for MYD88L265P 178
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL) 177
Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients 176
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 175
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 175
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. 174
Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. 173
ESMO Consensus Conference on malignant lymphoma: General perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma 173
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 173
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma 172
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 171
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 171
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. 170
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 170
Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients 169
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 169
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 168
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. 168
Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2 167
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 167
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 166
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients 165
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 164
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 164
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS 164
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 164
Totale 27.642
Categoria #
all - tutte 121.011
article - articoli 0
book - libri 0
conference - conferenze 38.876
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.887


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.356 0 0 0 0 96 88 433 173 78 311 602 575
2022/20233.740 395 319 88 371 299 930 265 249 451 121 135 117
2023/20241.547 202 335 113 67 87 257 37 94 9 72 76 198
2024/20254.582 19 219 185 447 1.165 237 186 222 467 344 408 683
2025/20269.579 998 314 576 981 1.030 473 1.302 376 817 659 418 1.635
2026/20274.310 490 908 811 1.573 528 0 0 0 0 0 0 0
Totale 43.827